Physician profile
Jonathan Lo
NPI 1285096289
$4,075.70
in general payments reported to CMS, 2019-2025
17 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $119 · 2021: $433 · 2022: $534 · 2023: $576 · 2024: $883 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005 · Long Term Medical Supply Or Device Loan: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.13 |
| Long Term Medical Supply Or Device Loan | $838.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,314.94 | 2021-2025 | Unity, Hydrus Microstent, Clareon |
| Abbvie INC. | $490.14 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $286.95 | 2023-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $266.32 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $263.34 | 2021-2025 | Cequa |
| Sight Sciences, INC. | $225.08 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $191.62 | 2019-2021 | |
| Genentech USA, INC. | $189.64 | 2022-2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $172.97 | 2024-2025 | Xdemvy |
| Allergan, INC. | $166.21 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $151.98 | 2021-2022 | |
| Rxsight INC | $119.56 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Novartis Pharmaceuticals Corporation | $107.93 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.83 | 2021 | |
| Amgen INC. | $33.74 | 2024 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $32.05 | 2025 | Ryzumvi, Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.